Skip to main content
. Author manuscript; available in PMC: 2012 Dec 17.
Published in final edited form as: Crit Care Med. 2011 Jun;39(6):1439–1447. doi: 10.1097/CCM.0b013e3182120691

Table 2.

Serial mean (±SEM) arterial blood pressure over 24 hrs of measurement in animals receiving W1-mAb in 1× or 10× molar doses of protective antigen or placebo at the time of (0 hrs) or 6 or 12 hrs after the start of anthrax toxin or diluent infusions

Challenge Treatment Treatment Time (hrs) Time (hrs) After Initiation of Anthrax Toxin Infusion
0 2 4 6 8 10 12 14 16 18 20 22 24
Diluent Placebo —c 114 ± 2 118 ± 2 119 ± 2 119 ± 2 119 ± 3 119 ± 3 117 ± 2 118 ± 3 118 ± 3 117 ± 4 121 ± 3 114 ± 3 119 ± 3
ET Placeboa 0 118 ± 4b 113 ± 5 105 ± 6 103 ± 5 104 ± 4 101 ± 4 92 ± 6 95 ± 5 86 ± 6 90 ± 5 87 ± 5 81 ± 8 70 ± 9
1× 119 ± 3 122 ± 4 118 ± 4 120 ± 4 114 ± 3 115 ± 5 114 ± 4 114 ± 5 114 ± 5 112 ± 6 117 ± 6 110 ± 7 109 ± 6
10× 120 ± 4 126 ± 3 123 ± 3 121 ± 4 117 ± 4 112 ± 3 112 ± 4 111 ± 3 114 ± 3 112 ± 3 112 ± 4 120 ± 6 112 ± 5
Placeboa 6 115 ± 2 115 ± 3 107 ± 3 104 ± 4 105 ± 3 103 ± 3 105 ± 3 93 ± 4 91 ± 3 86 ± 3 86 ± 4 79 ± 5 76 ± 4
1× 120 ± 4 114 ± 4 103 ± 4 101 ± 3 104 ± 3 104 ± 4 104 ± 4 99 ± 4 98 ± 3 95 ± 2 98 ± 3 94 ± 3 90 ± 3
10× 112 ± 2 124 ± 7 109 ± 6 98 ± 6 97 ± 7 94 ± 7 94 ± 6 96 ± 9 98 ± 9 95 ± 9 95 ± 9 94 ± 9 93 ± 9
Placeboa 12 110 ± 4 121 ± 4 111 ± 4 107 ± 5 105 ± 4 96 ± 6 94 ± 6 91 ± 5 88 ± 5 83 ± 5 74 ± 8 78 ± 5 73 ± 9
1× 113 ± 3 109 ± 3 101 ± 2 105 ± 5 100 ± 5 108 ± 4 105 ± 5 100 ± 4 96 ± 2 95 ± 5 98 ± 7 94 ± 7 94 ± 6
10× 114 ± 2 123 ± 11 125 ± 10 108 ± 5 109 ± 4 108 ± 5 106 ± 3 103 ± 3 102 ± 3 97 ± 3 91 ± 4 96 ± 2 91 ± 2
LT Placeboa 0 112 ± 3 120 ± 5 114 ± 4 102 ± 5 98 ± 7 94 ± 8 97 ± 10 105 ± 10 105 ± 7 110 ± 6 111 ± 7 105 ± 3 109 ± 5
1× 108 ± 4 113 ± 5 111 ± 4 112 ± 4 111 ± 5 113 ± 5 112 ± 4 109 ± 5 109 ± 4 107 ± 4 107 ± 5 101 ± 4 100 ± 5
10× 112 ± 2 118 ± 3 114 ± 4 113 ± 4 108 ± 3 108 ± 3 105 ± 3 106 ± 2 109 ± 3 115 ± 4 111 ± 3 110 ± 4 111 ± 5
Placeboa 6 117 ± 2 120 ± 3 121 ± 3 115 ± 4 102 ± 5 105 ± 6 101 ± 9 105 ± 8 114 ± 4 109 ± 5 113 ± 5 112 ± 5 121 ± 7
1× 114 ± 3 121 ± 3 117 ± 3 112 ± 5 104 ± 5 108 ± 4 110 ± 4 109 ± 4 111 ± 4 113 ± 3 112 ± 4 111 ± 3 106 ± 2
10× 113 ± 2 119 ± 3 119 ± 4 105 ± 6 109 ± 7 107 ± 4 109 ± 7 113 ± 6 116 ± 7 117 ± 3 116 ± 7 115 ± 6 113 ± 5
Placeboa 12 116 ± 2 121 ± 3 114 ± 3 110 ± 2 106 ± 3 101 ± 5 103 ± 5 112 ± 4 112 ± 4 109 ± 4 113 ± 4 111 ± 4 110 ± 5
1× 111 ± 2 117 ± 2 115 ± 3 112 ± 3 107 ± 4 95 ± 5 102 ± 7 95 ± 8 101 ± 10 104 ± 10 119 ± 5 117 ± 6 107 ± 4
10× 115 ± 4 118 ± 3 106 ± 4 101 ± 6 99 ± 6 99 ± 6 107 ± 5 114 ± 6 112 ± 4 118 ± 6 128 ± 4 122 ± 14 124 ± 6
ET + LT Placeboa 0 114 ± 2 117 ± 3 113 ± 3 100 ± 3 93 ± 6 90 ± 7 95 ± 6 102 ± 6 110 ± 5 107 ± 7 109 ± 2 107 ± 3 106 ± 6
1× 122 ± 3 116 ± 4 118 ± 4 119 ± 4 116 ± 4 115 ± 4 115 ± 4 118 ± 4 115 ± 5 111 ± 5 119 ± 4 120 ± 4 115 ± 5
10× 116 ± 3 120 ± 3 114 ± 3 117 ± 3 118 ± 3 118 ± 4 120 ± 5 123 ± 3 120 ± 5 123 ± 4 124 ± 4 124 ± 3 121 ± 4
Placeboa 6 118 ± 2 126 ± 2 114 ± 3 98 ± 3 86 ± 4 106 ± 4 110 ± 3 101 ± 6 111 ± 3 109 ± 2 111 ± 4 106 ± 4 106 ± 3
1× 118 ± 3 127 ± 3 119 ± 3 101 ± 4 93 ± 5 94 ± 7 100 ± 9 110 ± 8 116 ± 4 113 ± 4 108 ± 8 115 ± 4 114 ± 5
10× 115 ± 5 122 ± 3 115 ± 3 96 ± 7 94 ± 9 117 ± 3 112 ± 5 120 ± 5 122 ± 6 122 ± 7 126 ± 6 125 ± 10 123 ± 9
Placeboa 12 115 ± 3 124 ± 3 117 ± 3 96 ± 3 89 ± 4 91 ± 5 99 ± 6 114 ± 4 114 ± 8 107 ± 3 103 ± 6 109 ± 4 101 ± 6
1× 114 ± 3 120 ± 2 115 ± 2 97 ± 5 91 ± 6 112 ± 7 110 ± 7 107 ± 8 111 ± 5 106 ± 6 112 ± 6 113 ± 7 109 ± 7
10× 116 ± 4 125 ± 4 114 ± 5 100 ± 6 101 ± 4 105 ± 4 102 ± 7 96 ± 9 101 ± 9 98 ± 10 105 ± 3 108 ± 4 101 ± 4

W1-mAb is a chimpanzee-derived monoclonal antibody against protective antigen.

a

Compared to diluent challenge, edema toxin with placebo treatment produced progressive decreases in the mean arterial blood pressure throughout (p < .0001 for the interaction with time averaged over placebo groups), while challenges with lethal toxin alone or lethal toxin together with edema toxin produced decreases in mean arterial blood pressure that were resolved by 24 hrs (p ≤ .004 for the interaction with time averaged over respective placebo groups). See Results for a full description of these comparisons;

b

bold values were employed to compare over similar periods of time (12 hrs) the effects of W1-mAb administered at different time points. The levels of significance for the overall effects of W1-mAb and interaction of this effect and time are shown in Figure 2;

c

treatment at 0, 6, or 12 hrs (see Material and Methods).